Lung Cancer
News
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
News
RCT confirms CT scan screening catches lung cancer early
CT screening of older people with heavy smoking histories – using lesion volume, not diameter, as a trigger for further work-up – reduced lung...
News
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
Reductions in smoking are largely responsible for the lung cancer progress, while immunotherapy and targeted treatments have improved survival in...
News
Large state disparities seen for lung cancer screening
Lung cancer screening for high-risk individuals remains low.
News
Not all lung cancer patients receive treatment
Reasons include metastasis and refusal, and rates by state vary from 8% to 30%, the American Lung Association reports.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
News
Lorlatinib induces deep responses in ROS1-positive NSCLC
Among 40 crizotinib-pretreated patients, 14 patients (35%) had an objective response on lorlatinib, with a median duration of response of 13.8...
News
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
Conference Coverage
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
Conference Coverage
Patients have good recall on lung cancer screening scan benefits, not risks
NEW ORLEANS – Results suggest need for ongoing patient education beyond the initial shared decision-making encounter.
